Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook

Key Points Ionis has six commercial therapies, mostly focused on rare diseases. Zanvastro treats Alexander disease, a brain disorder. The company may still be years away from being profitable. 10 stocks we like better than Ionis Pharmaceuticals › Shares of Ionis Pharmaceuticals (NASDAQ: IONS) are down more than 40% so far this year and are almost half of their 52-week high of $86.74. While there are plenty of valid reasons for that tumble, analysts still average a lofty price target of $83.82 for the stock, with most putting it as a buy or a strong buy.